Prednisone is not a recommended treatment for most people with interstitial cystitis (IC). Both the American Urological Association and the European Association of Urology advise against long-term oral corticosteroids for this condition, citing a lack of strong evidence and a side effect profile that outweighs the potential benefits. There is, however, one important exception: a specific subtype of IC involving Hunner lesions, where low-dose prednisone has shown meaningful results in small studies.
Why Prednisone Seems Like It Should Work
IC involves chronic bladder inflammation, and prednisone is one of the most widely used anti-inflammatory drugs in medicine. The logic is straightforward. IC is linked to overactive immune cells called mast cells that release histamine, prostaglandins, and other inflammatory chemicals into the bladder wall. Prednisone suppresses this immune activity, reduces the production of those inflammatory substances, and can calm ectopic nerve signals firing from inflamed tissue. On paper, it targets several of the pathways thought to drive IC pain and urgency.
IC also overlaps with other inflammatory and autoimmune conditions like fibromyalgia, inflammatory bowel disease, lupus, and Sjögren’s syndrome, all of which sometimes respond to corticosteroids. This overlap gives biological plausibility to the idea that prednisone could help IC too.
What the Evidence Actually Shows
Despite that plausibility, the clinical evidence is thin. No large, well-designed randomized trials have demonstrated that oral prednisone reliably improves IC symptoms across the broader patient population. The studies that do exist are small, retrospective, and focused on patients with a specific inflammatory subtype.
The most cited study followed 14 patients with severe, treatment-resistant ulcerative IC. Among the full group, pain improved by 69% and overall symptom scores dropped by 22%. Nine of the 14 patients (64%) were still taking prednisone after an average of 16 months, and those nine saw a 38% reduction in symptom scores along with an 88% drop in pain. These are notable improvements, but the study was small and had no control group, making it hard to draw firm conclusions.
A more recent retrospective study from Japan looked at 31 patients with refractory Hunner-type IC treated with low-dose oral prednisolone (starting at 5 to 7.5 mg daily). The response rate climbed over time: about 39% of patients responded at one month, rising to roughly 65% at 12 months. Bladder pain and symptom scores improved significantly within the first month, while urinary frequency and quality of life took longer, showing meaningful gains around nine months. The dose was gradually tapered to the lowest amount that maintained relief, landing around 3 mg daily by the one-year mark.
Hunner Lesions Make the Difference
The patients who seem to benefit from prednisone almost all have Hunner lesions, which are distinct inflammatory patches on the bladder wall found in roughly 5% to 10% of people diagnosed with IC. This subtype behaves more like a classic inflammatory disease, which is why it responds to anti-inflammatory treatment in a way that non-ulcerative IC typically does not.
If you have IC without Hunner lesions, the current evidence does not support using prednisone. The American Urological Association’s 2022 guidelines specifically state that systemic oral glucocorticoids “should not be offered” for IC, placing them in a category of treatments that lack efficacy or carry unacceptable side effects. The European Association of Urology echoes this with a strong recommendation against oral corticosteroids for long-term use. These guidelines are written with the general IC population in mind, where there simply isn’t enough evidence of benefit.
Risks of Long-Term Use
The side effect profile is a major reason guidelines discourage prednisone for IC. Short courses of a few days rarely cause serious problems, but IC is a chronic condition, and the patients who responded in studies were on prednisone for months or years.
Long-term prednisone use suppresses your immune system, increasing your vulnerability to infections ranging from common colds to more serious bacterial illnesses. Bone loss is another significant concern. Some people lose 10% to 20% of their bone mass within the first six months of steroid treatment, substantially raising fracture risk. Other common effects include weight gain, elevated blood sugar, high blood pressure, mood changes, and difficulty sleeping. In the Japanese study, two of 31 patients developed high blood pressure or glucose intolerance, though both were manageable and no one had to stop treatment because of side effects.
For a condition like Hunner-type IC, where other treatments have already failed, these trade-offs may be acceptable under close monitoring. For the broader IC population, the risks are harder to justify when the benefit is uncertain.
Steroid Injections as an Alternative
For patients with Hunner lesions, there is another option that avoids systemic side effects: direct injection of a corticosteroid into the lesions during a cystoscopy procedure. This approach delivers the drug exactly where it’s needed while limiting exposure to the rest of the body. It has been used in patients who did not respond to oral medications or bladder instillations and avoids the bone loss, immune suppression, and metabolic effects that come with taking steroids by mouth over many months.
Where Prednisone Fits in IC Treatment
Prednisone is not a first, second, or even third-line option for IC. The standard treatment approach starts with behavioral changes, dietary modifications, and stress management, then moves through oral medications like amitriptyline or hydroxyzine, bladder instillations, and physical therapy before considering more invasive options. Prednisone occupies a narrow role: it may help a subset of patients with confirmed Hunner lesions who have not responded to other therapies.
If your doctor has prescribed a short course of prednisone to manage a severe IC flare, that’s a different situation from long-term use. A brief taper over a week or two carries far fewer risks than months of daily dosing. But as an ongoing treatment strategy for typical IC, the evidence is not there to support it, and the guidelines explicitly recommend against it.